Grow Your Wealth
with Mutual Funds
Nippon India Nifty Pharma Etf-growth
Equity
Large Cap
Very High Risk
Latest AUM
₹ 1,247.9 Cr.
NAV as on 27 jul, 2026
₹ 26.68
+20.58%
3 years annulised
This Fund
Fund Details
Fund Names
Nippon India Nifty Pharma Etf-growth
Inception Date
02 Jul 2021
Lock In
No Lock-in
Risk
Principal at very high risk
Category Average Annual Returns
6.04
Portfolio Composition Analysis
Equity
99.90%
Cash
0.10%
Portfolio Updated on: 10 Jul, 2026
Sector Allocations
Equity
Healthcare
Portfolio Updated on: 27 jul, 2026
Top 10 Holdings
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 22.91% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 23.17% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 21.93% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 22.18% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 22.18% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 22.05% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 21.98% |
Debt & Credit Risk Analysis
| Alpha | -0.55% |
| Beta | 0.96% |
| Sharpe Ratio | 0.98% |
| Standard Deviation | 16.84% |
Returns Analysis
| Tenure | Absolute | Annualised | Category Average |
|---|---|---|---|
| 3 Months | 12.23% | NA | 6.12% |
| 6 Months | 19.56% | NA | 12.92% |
| 9 Months | 16.72% | NA | 4.47% |
| 1 Year | 14.83% | 14.83% | 6.04% |
| 2 Years | 21.22% | 10.10% | 24.93% |
| 3 Years | 76.28% | 20.80% | 25.71% |
| 5 Years | 89.94% | 13.69% | 19.91% |
Nippon India Nifty Pharma Etf-growth is one Equity mutual fund offered by Nippon India Mutual Fund. Launched on 02 Jul 2021, the fund aims Long term capital growth. Investment in equity and equity related securities and portfolios replicating the composition of Nifty Pharma Index, subject to tracking errors. It manages assets worth ₹1,247.9 crore as on Tue Mar 31, 2026. The expense ratio stands at 0.21%.
Jitendra Tolani has experience Prior to joining Nippon Mutual Fund, he was working with Motilal Oswal Financial Services Ltd, Asit C Mehta Investment Interrmediaries Ltd.
Top Performing Mutual Funds
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More Funds from Nippon India Mutual Fund
| Fund name | |||||||
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-idcw | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
growth is based on 1-month returns of the funds
Top Mutual Funds
| Fund name | |||||||
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-growth | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-idcw | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth | 6,293.1 | +1.81% | +9.15% | +16.35% | +6.18% | +23.07% | +15.99% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth | 6,293.1 | +1.88% | +9.37% | +16.82% | +7.07% | +24.11% | +17.02% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw | 6,293.1 | +1.88% | +9.37% | +16.82% | +7.07% | +24.11% | +17.02% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw | 6,293.1 | +1.81% | +9.15% | +16.35% | +6.18% | +23.07% | +15.99% |
Top funds are based on Fund AUM
Top Equity Funds
| Fund name | ||||
|---|---|---|---|---|
| Sbi Healthcare Opportunities Fund Direct Plan-growth | ₹585.48 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-growth | ₹585.48 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-idcw | ₹406.78 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-idcw | ₹406.78 | +23.82% | +18.25% | — |
| Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth | ₹47.15 | +24.11% | +17.02% | — |
| Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw | ₹28.47 | +24.11% | +17.02% | — |
| Sbi Healthcare Opportunities Fund-growth | ₹506.05 | +22.55% | +17.02% | — |
| Sbi Healthcare Opportunities Fund-idcw | ₹318.78 | +22.55% | +17.02% | — |
| Mirae Asset Healthcare Fund Direct-growth | ₹50.72 | +23.36% | +16.17% | — |
| Mirae Asset Healthcare Fund Direct-idcw | ₹30.55 | +23.36% | +16.17% | — |
growth is based on 5Y returns of the funds
Historical NAV
| Date | NAV |
|---|---|
| 27 Jul 2026 | ₹26.68 |
| 24 Jul 2026 | ₹26.27 |
| 23 Jul 2026 | ₹26.37 |
| 22 Jul 2026 | ₹26.47 |
| 21 Jul 2026 | ₹26.82 |
| 20 Jul 2026 | ₹26.73 |
| 17 Jul 2026 | ₹26.36 |
| 16 Jul 2026 | ₹26.72 |
| 15 Jul 2026 | ₹26.72 |
| 14 Jul 2026 | ₹26.62 |
| 13 Jul 2026 | ₹26.35 |
| 10 Jul 2026 | ₹26.38 |
| 09 Jul 2026 | ₹26.35 |
| 08 Jul 2026 | ₹26.12 |
| 07 Jul 2026 | ₹26.37 |
| 06 Jul 2026 | ₹26.55 |
| 03 Jul 2026 | ₹26.43 |
| 02 Jul 2026 | ₹25.98 |
| 01 Jul 2026 | ₹25.85 |
| 30 Jun 2026 | ₹26.00 |
| 29 Jun 2026 | ₹25.90 |
| 25 Jun 2026 | ₹25.63 |
| 24 Jun 2026 | ₹25.68 |
| 23 Jun 2026 | ₹25.65 |
| 22 Jun 2026 | ₹25.42 |
| 19 Jun 2026 | ₹25.11 |
| 18 Jun 2026 | ₹24.93 |
| 17 Jun 2026 | ₹24.79 |
| 15 Jun 2026 | ₹24.86 |
| 12 Jun 2026 | ₹25.03 |
Portfolio Updated on: 28 Jul, 2026
Fund Growth & Size Analysis
+₹1,247.9 Cr
Since Launch
This Fund
Category Average
Compare Mutual funds
Nippon India Nifty Pharma Etf-growth Returns Comparison
Compare Nippon India Nifty Pharma Etf-growth with any MF,
EYF, stock or index
Jan 1, 2026 – Feb 1, 2026
Nippon India Nifty Pha....
No funds found for your search.
Nippon India Nifty Pharma Etf-growth FAQ'S
- Sharpe Ratio: 0.98%
- Standard Deviation: 16.84%
- Beta: 0.96%
- Alpha: -0.55%
Additional important ratios:
As of Tue Mar 31, 2026, the total assets managed under Nippon India Nifty Pharma Etf-growth stand at approximately ₹ 1,247.9 crore.
The Nippon India Nifty Pharma Etf-growth has delivered the following short-term performance:
- 3 Months Return: 12.23%
- 6 Months Return: 19.56%
The historical growth of the Nippon India Nifty Pharma Etf-growth is reflected through its CAGR returns:
- 3 Year CAGR: 20.80%
- 5 Year CAGR: 13.69%
- Return Since Launch: 12.71%
The portfolio of Nippon India Nifty Pharma Etf-growth is distributed across different asset classes as follows:
- Equity: 99.90%
- Other Assets: 0.10%
The Nippon India Nifty Pharma Etf-growth is managed by Jitendra Tolani, representing Nippon India Mutual Fund.
The Nippon India Nifty Pharma Etf-growth investments are allocated across market caps in the following manner:
- Large Cap Stocks: 1.00%
- Mid Cap Stocks: 1.00%
- Small Cap Stocks: 1.00%
Top stock holdings of Nippon India Nifty Pharma Etf-growth include:
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 22.91% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 23.17% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 21.93% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 22.18% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 22.18% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 22.05% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 21.98% of the portfolio
Major sector exposures in Nippon India Nifty Pharma Etf-growth are:
- Healthcare – accounts for 959.63% of the portfolio
